Preexisting autoimmune diseases are tied to shorter hospital stays and less toxicity risk in patients receiving chimeric ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
This study provides valuable insights into the role of the NF-kB and IKK signaling pathways in γδ T cell development and survival, using robust genetic mouse models. While the research is ...
The deadline to make a claim in the $177 million settlement is coming soon. Here's what customers should know.
From silver nanofibers to smart, sensory-packed dressings, the next generation of wound-healing technology is blurring the ...
Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gr ...
For patients across all indications treated within the RP2D range early, promising progression-free survival (PFS) and ...
Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...
Details for the Company’s ASH abstracts and oral presentation can be found here: Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us.
Pharmaceutical Technology on MSN
Estonia’s digital health DNA: Trust, data, and biotech in focus
From e-health records to a biotech hub in Tartu, Estonia is harnessing data, digital infrastructure, and investment to drive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback